BioSpace News Archive

CalciMedica Inc. announced that there will be a presentation of data from the initial cohort of the CRSPA study of Auxora™ in asparaginase-induced pancreatic toxicity in a poster presentation at the 65th Annual American Society of Hematology Meeting & Exposition being held December 9-12, 2023 in San Diego, CA.

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) (“Therma” or the “Company”), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today the Company

Wugen, Inc. will be presenting four abstracts, now available online, at the American Society of Hematology Annual Meeting and Exposition Dec. 9-12.

Mineralys Therapeutics, Inc. presented a new post-hoc analysis from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension and resistant hypertension.

Otsuka Pharmaceutical Development & Commercialization, Inc. and Visterra Inc., today announced that the full results of a Phase 2 trial of sibeprenlimab (VIS649) for treatment of immunoglobulin A nephropathy (IgAN; Berger’s disease) have been published in the New England Journal of Medicine.

Kane Biotech Inc. in partnership with ProgenaCare Global LLP announces the launch of the newly rebranded revyve™ Antimicrobial Wound Gel.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs) today announced that it will present new preclinical data in an oral presentation at the 65th Annual Meeting of the American Society of Hematology (ASH) taking place December 9-12, 2023, in San Diego, California.

Seagen Inc. (NASDAQ: SGEN) today announced that 12- and 24-month progression free survival data will be presented for an ADCETRIS® (brentuximab vedotin) and immunotherapy combination in early and advanced stage classical Hodgkin lymphoma (cHL), respectively.

Karyopharm Therapeutics Inc. today announced that several abstracts that include selinexor data in myelofibrosis (MF) have been selected for presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 9-12, 2023, in San Diego, CA.

Mustang Bio, Inc. announced that interim Phase 1/2 data from Mustang’s multicenter clinical trial of MB-106, a CD20-targeted, autologous CAR-T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia, have been selected for a poster presentation at the 65th American Society of Hematology Annual Meeting, taking place December 9-12, 2023 in San Diego.